ArticleJournal of proteome research2026
Proteome Remodeling of a Carbapenem-Resistant Escherichia coli Strain upon Meropenem Exposure.
Article in Journal of proteome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Carbapenem-resistant Escherichia coli poses a serious threat to global health, with limited treatment options and potentially fatal outcomes. Beyond horizontally acquired resistance genes, other cellular pathways are remodeled in the resistant phenotype, but these systemic responses remain poorly understood. Here, tandem mass tag-based quantitative proteomics was used to characterize the response of E. coli strain CCUG 70745 to Meropenem. Two inhibitory concentrations (128 and 192 μg/mL), anchored to the MIC of the isolate (128 μg/mL), were compared with an antibiotic-free control after 15 min. The analysis quantified 60% of the theoretical proteome, identifying 172 and 813 differentially expressed proteins at 128 and 192 μg/mL, respectively. Canonical resistance determinants, including β-lactamases and efflux pumps, were altered, as well as proteins involved in cell-wall formation, membrane transport, and signal transduction. Gene set enrichment analysis highlighted oxidative phosphorylation, ABC transporters, two-component systems, and cofactor metabolism. Increased abundances of two-component-system and membrane-integrity proteins were consistent with a coordinated, dose-dependent stress response, and interaction networks linked a cell-division module to efflux and metabolic adaptation. These results suggest that Meropenem engages both primary and auxiliary resistance-associated processes, providing a proteomic framework that may guide therapies targeting bacterial metabolism and membrane functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.